<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00709969</url>
  </required_header>
  <id_info>
    <org_study_id>CCOA566A2403</org_study_id>
    <nct_id>NCT00709969</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets in African Infants and Children With Uncomplicated P. Falciparum Malaria</brief_title>
  <official_title>Open Label, Multicenter Study for Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets (6-Dose Regimen) in African Infants and Children in the Treatment of Acute Uncomplicated Falciparum Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Avenue Appia 20</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH - 1211 Geneva 27</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of artemether-lumefantrine tablets (6-dose
      regimen) in African infants / children with acute uncomplicated falciparum malaria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">February 2003</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, SAEs; hematology and biochemistry parameters; electrocardiogram; urine values; vital signs; physical neurological examinations; and neurological examinations</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients free of parasites at 7, 14 and at 28 days</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clearance from parasites (asexual forms)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clearance of fever</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clearance of gametocytes (parasite sexual forms)</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">310</enrollment>
  <condition>Plasmodium Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Artemether-lumefantrine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine</intervention_name>
    <description>20mg artemether and 120 mg lumefantrine, tablet, dose based on body weight, 3 days treatment 5 - &lt; 10kg (BWG 1) = 6 doses of 1 tablet / 10 - &lt; 15kg (BWG 2) = 6 doses of 1 tablet / 15 - ≤ 25kg (BWG 3) = 6 doses of 2 tablets</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Coartem®, Riamet®, co-artemether</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female weighing ≥ 5kg and ≤ 25kg

          -  P. falciparum parasitemia between 1,000 and 100,000 parasites/mm3

          -  with confirmed diagnosis of uncomplicated malaria caused P. falciparum parasite

        Exclusion Criteria:

          -  complicated malaria

          -  ingestion of various antimalarial drugs, or other drugs influencing cardiac function
             in the previous 4 weeks before study entry to 8 weeks

          -  severe anaemia

          -  severe malnutrition

          -  malaria due to other than P. falciparum

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kemri-Wellcome Trust Programme</name>
      <address>
        <city>Kilifi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital Malaria Research Laboratories Institute for Advance Medical Research and Training</name>
      <address>
        <city>Ibadan</city>
        <country>Nigeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Muhimbili University College of Health Sciences Department of Parasitology and Medical Entomology, Box 65011</name>
      <address>
        <city>Dar es Salaam</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Nigeria</country>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2008</study_first_submitted>
  <study_first_submitted_qc>July 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2008</study_first_posted>
  <last_update_submitted>July 2, 2008</last_update_submitted>
  <last_update_submitted_qc>July 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>co-artemether</keyword>
  <keyword>auditory</keyword>
  <keyword>Plasmodium falciparum</keyword>
  <keyword>marsh fever</keyword>
  <keyword>remittent fever</keyword>
  <keyword>artemether</keyword>
  <keyword>artemisinins</keyword>
  <keyword>lumefantrine</keyword>
  <keyword>child</keyword>
  <keyword>infant</keyword>
  <keyword>Africa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

